- Home
- HALO vs BBIO Comparison
HALO vs BBIO Comparison
Compare HALO & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HALO
- BBIO
- Stock Information
- Founded
- HALO 1998
- BBIO 2015
- Country
- HALO United States
- BBIO United States
- Employees
- HALO N/A
- BBIO N/A
- Industry
- HALO Biotechnology: Biological Products (No Diagnostic Substances)
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- HALO Health Care
- BBIO Health Care
- Exchange
- HALO Nasdaq
- BBIO Nasdaq
- Market Cap
- HALO 7.4B
- BBIO 8.0B
- IPO Year
- HALO N/A
- BBIO 2019
- Fundamental
- Price
- HALO $52.80
- BBIO $45.60
- Analyst Decision
- HALO Buy
- BBIO Strong Buy
- Analyst Count
- HALO 9
- BBIO 14
- Target Price
- HALO $63.56
- BBIO $58.85
- AVG Volume (30 Days)
- HALO 2.9M
- BBIO 3.3M
- Earning Date
- HALO 08-05-2025
- BBIO 07-31-2025
- Dividend Yield
- HALO N/A
- BBIO N/A
- EPS Growth
- HALO 55.40
- BBIO N/A
- EPS
- HALO 3.76
- BBIO N/A
- Revenue
- HALO $1,084,306,000.00
- BBIO $127,415,000.00
- Revenue This Year
- HALO $25.77
- BBIO $102.05
- Revenue Next Year
- HALO $18.01
- BBIO $54.69
- P/E Ratio
- HALO $14.37
- BBIO N/A
- Revenue Growth
- HALO 25.64
- BBIO N/A
- 52 Week Low
- HALO $42.01
- BBIO $21.72
- 52 Week High
- HALO $70.51
- BBIO $45.48
- Technical
- Relative Strength Index (RSI)
- HALO 50.36
- BBIO 66.67
- Support Level
- HALO $51.06
- BBIO $41.80
- Resistance Level
- HALO $54.25
- BBIO $45.48
- Average True Range (ATR)
- HALO 1.22
- BBIO 1.57
- MACD
- HALO 0.23
- BBIO -0.01
- Stochastic Oscillator
- HALO 84.97
- BBIO 78.42
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.